Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.946 – $1.03
Volume58,788
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.15M
Price / earnings
—
Price / book
0.47×
Price / sales
0.42×
EV / sales
0.4×
EV / EBITDA
-0.59×
Profitability
Earnings per share
-$2.15
Return on assets
-65.05%
Return on equity
-106.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.13×
Current ratio
2.07×
Quick ratio
1.54×
Cash ratio
0.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.09M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BNGO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$8.28M
$8.17M
$6.69M
$7.95M
$7.37M
$6.73M
$6.46M
$8.16M
Cost of revenue
$4.33M
$3.86M
$3.44M
$4.55M
$4M
$3.26M
$3.52M
$4.75M
Gross profit
$3.95M
$4.31M
$3.25M
$3.4M
$3.37M
$3.48M
$2.94M
$3.42M
Selling, general and administrative
$7.44M
$8.54M
$8.01M
$8.71M
$9.06M
$8.35M
$9.03M
$11.75M
Research and development
$3.04M
$2.99M
$3.14M
$3.23M
$2.84M
$2.93M
$2.37M
$3.47M
Total operating expenses
$10.49M
$11.53M
$11.15M
$11.94M
$11.91M
$11.28M
$11.4M
$15.36M
Operating income
-$6.54M
-$7.22M
-$7.9M
-$8.54M
-$8.54M
-$7.8M
-$8.47M
-$11.94M
Interest expense
$63K
$76K
$223K
$0
$268K
$204K
$290K
$0
Income before taxes
-$6.45M
-$7.42M
-$8.29M
-$7.9M
-$8.49M
-$6.85M
-$3.1M
-$20.12M
Income taxes
$8K
$7K
$10K
$35K
$14K
$10K
$7K
$1K
Net income
-$6.45M
-$7.42M
-$8.3M
-$7.93M
-$8.5M
-$6.86M
-$3.1M
-$20.13M
Net income attributable to common shareholders
-$6.45M
-$7.42M
-$8.3M
-$7.93M
-$8.5M
-$6.86M
-$3.1M
-$20.13M
EBITDA
-$4.25M
-$4.92M
-$5.59M
-$6.2M
-$6.16M
-$5.42M
-$6.03M
-$9.41M
Basic earnings per share
-$0.54
-$0.64
-$0.76
-$0.77
-$1.59
-$1.99
-$1.15
-$12.21
Diluted earnings per share
-$0.54
-$0.64
-$0.76
-$0.77
-$1.59
-$1.99
-$1.15
-$12.21
Recent news
Company coverage with links to the original publishers.
Sarepta Therapeutics (SRPT) reported quarterly earnings of $0.13 per share, missing consensus estimates of $0.37 per share, representing a -64.87% earnings surprise. While revenues of $381.35 million exceeded expectations by 9.43%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions. The stock has underperformed the S&P 500 by 24.1% year-to-date.
Bionano Genomics completed a public offering of 5 million shares and warrants, raising approximately $10 million gross proceeds to be used for working capital and general corporate purposes.
Bionano Genomics has priced a public offering of 5 million shares and accompanying warrants at $2.00 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.
Bionano Genomics announced a $10 million registered direct offering, with the proceeds to be used for general corporate purposes. The offering includes the sale of common stock and warrants to institutional investors.
Bionano Genomics announced an amendment to its senior secured convertible debentures, which defers near-term debt payments and reduces cash needs, strengthening the company's capital structure and improving its near-term liquidity position.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.